HSPA5 and metabolic dysfunction-associated steatohepatitis: As the HSPA5 decrease in PCLSs is in line with observations in NAFLD/NASH patients [68,69], it might be interesting to study the relation between ER stress, UPR, and fatty liver disease in this PCLS model.